Investor Presentation

12th August 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Pheroze Jeejeebhoy Tower, Bandra-Kurla Complex, Bandra (E), Dalal Street, Mumbai- 400 001 Mumbai - 400 051 Security Code: 524164 Security Symbol: IOLCP Subject: Investor Presentation-Q1 FY27. Dear Sir, Please find enclosed herewith the Investor Presentation on the Financial Results of the Company for the quarter ended 30th June 2026. This presentation is being submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This presentation is also made available on the Company’s website www.iolcp.com Hope you will find the same in order. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q1FY27 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by IOL Chemicals and Pharmaceuticals Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Q1 FY27 Performance Q1 FY27 Standalone Performance Highlights ₹ 756.3 Cr Q1 FY27 ₹ 64.5 Cr ₹ 111.7 Cr Revenue from Operations EBITDA 37.1% YoY 60.7% YoY 89.9% YoY EBITDA Margin 14.6% PAT Margin 8.4% FY26 ₹ 2,319.1 Cr ₹ 290.4 Cr ₹ 137.7 Cr Revenue from Operations EBITDA PAT 11.5% YoY 29.3% YoY 36.4% YoY EBITDA Margin 12.4% PAT Margin 5.9% Q1 FY27 Standalone Performance Highlights Pharmaceuticals Chemicals (Net of intersegment) Geographical Break-up (In ₹ Cr) (In ₹ Cr) 1396.3 469.5 922.8 286.8 29% 866.9 1212.3 244.9 374.5 222.4 329.3 172.3 62.2 68.8 126.3 40.1 15.4 30.2 5.9 12.8 17.3 FY25 FY26 Q1 FY26 Q4 FY26 Q1 FY27 FY25 FY26 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY27 EBIT Revenue EBIT Revenue Exports Domestic Standalone Profit & Loss Statement – Q1 FY27 Particulars (in INR Cr.) Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q FY26 Revenue from Operations 756.3 551.7 37.1% 619.5 22.1% 2319.1 Other Income 8.2 7.4 1.7 21.3 Total Revenue 764.4 559.1 36.7% 621.2 23.1% 2340.3 Cost of Materials Consumed 506.8 376.6 401.7 1501.6 Purchase of Traded Goods 0.8 0.0 3.8 4.0 Changes in Inventories of Finished Goods and Work in Progress -29.5 -12.3 -33.2 -18.5 Employee Benefits Expense 71.2 57.7 70.3 248.3 Other Expenses 103.5 67.7 84.3 314.6 EBITDA 111.7 69.5 60.7% 94.3 18.5% 290.4 EBITDA % 14.6% 12.4% 15.2% 12.4% Depreciation and Amortisation Expense 21.3 19.8 20.3 80.2 EBIT 90.4 49.8 81.7% 74.0 22.1% 210.2 Finance Costs 3.6 4.2 3.2 14.6 Profit before exceptional items and tax 86.8 45.5 70.8 195.7 Exceptional items* 0.0 0.0 0.0 11.2 PBT 86.8 45.5 90.5% 70.8 22.5% 184.4 Total Tax Expense 22.3 11.6 17.7 46.7 Profit after tax 64.5 34.0 89.9% 53.2 21.2% 137.7 PAT % 8.4% 6.1% 8.6% 5.9% EPS 2.20 1.16 1.81 4.69 At a Glance Our Journey- A Story of Resilience and Progress 1986-91 1996-99 2000-07 2009-13 2015-16 2017-18 2019 - 20 2021-22 2023 2024 2025 2026 • 1986: • 2000 – Production of • 2015 - Received US • 2019 - Commissioned • Increased • Commissioned new Paracetamol Unit-11 with Incorporation of Ibuprofen FDA EIR for Ibuprofen Unit 06 (Dedicated to Paracetamol capacity installed capacity of 10,800 the Company • 2007 - Commissioned • 2016 - Pantoprazole) to 3,600 TPA. • 1991: Listing on dedicated Ibuprofen Commissioned Unit • 2020 - Commissioned • Commissioned state MTPA. • Increased Clopidogrel BSE, Established Unit- 01. 03 for new product Unit 07 (Dedicated to of the art Acaic capacity to 240 MTPA from Acetic Acid plant. development Metformin) Anhydride Plant. 180 MTPA. • Incorporated IOL Pharmaxis UK Limited (wholly owned subsidiary) • Ethyl Acetate • 1996 - • 2009 - Commissioned • 2017 - Converted Unit-2 • 2021 Commissioned Successful completion of capacity increased Commissioned Ethyl IBB, MCA and Acetyl into a dedicated Unit-08 and Unit 10 Site Inspection by to 1,20,000 MTPA Acetate Plant Chloride plants. Ibuprofen facility (Multi-product facilities) ANVISA, Brazil GMP of all • Acetic Anhydride • 1999 – • 2010 - Commissioned 13 • 2018 Commissioned • 2022 Commenced 10 API’s manufacturing capacity increased Commissioned Acetic MW Co Generation Plant. Unit-04 (Dedicated to commercial production unit and received to 32,000 MTPA. Anhydride Plant. • 2012 - Commissioned Metformin) of Paracetamol with approval in May 2024. • Installed Triacetin Unit 02 (Multi product Commissioned Unit 05 installed capacity of Capacity of 6000 facility) (Clopidogrel and 1800 MTPA supported by MTPA • 2013 - Received EU-GMP Fenofibrate) backward integration. • Enhanced Capacity Certification. of Pantoprazole to 276 MTPA. Business Overview Team size of 3000+ employees Customer base across 80 countries Diversified API Company with Global Fully backward integrated Ibuprofen Leadership Supported by Paracetamol manufacturing facility Backward Integrated Manufacturing with capacity of 10,800 MTPA Platform Among the top global producers of Major producer of Ethyl Acetate in India DSIR-approved R&D facility with Iso Butyl Benzene (IBB) with a capacity of 1,20,000 MTPA, and 120 professionals, including more Acetic Anhydride with a capacity of than 50 scientists 32,000 MTPA Existing Facility: Spanning 180+ acres Zero Discharge Effluent Treatment Plant Responsible CARE Certification Expansion: Purchased 101 acres on Chandigarh- Recognized with Ecovadis Gold Medal Recipient: Retained the Respon [Showing first 8,000 characters — download PDF for full document]